Dr. William Williams reports

BRIACELL IMAGES CONFIRM ROBUST ANTI-TUMOR ACTIVITY IN PATIENT WITH "EYE-BULGING" METASTATIC BREAST CANCER

Briacell Therapeutics Corp. has released transformational images of the recently reported remarkable responder in the phase 2 study of Briacell's Bria-IMT combination regimen. The patient had metastatic breast cancer behind her eye, causing proptosis (eye-bulging) and significant pain that were both markedly reduced with Briacell's treatment.

"We are extremely excited to report significant tumour reduction in this very difficult to treat patient who had failed seven prior regimens including treatment with Enhertu, an antibody-drug conjugate, highlighting the robust anti-tumour activity of the Bria-IMT regimen in difficult-to-reach tumours such as those in the eye orbit. We observed significant tumour reduction along with significant eye pain reduction after only three cycles of treatment with the Bria-IMT combination regimen. The Bria-IMT regimen has been very well tolerated and the patient remains on treatment," stated Dr. William V. Williams, Briacell's president and chief executive officer. "We look forward to sharing additional data in the coming months."

Briacell had previously reported a similar case of a remarkable response with resolution of an eye-bulging orbital tumour. That particular patient had received (and failed) 12 regimens with 16 agents (including 13 chemotherapies) prior to Briacell's combination therapy, again adding to the remarkable nature of her response. These two patient responses are included in Briacell's recently reported 71-per-cent intracranial objective response rate (iORR) in breast cancer patients with central nervous system (CNS) metastases treated with Bria-IMT.

"Today's reported MRI imaging confirms the clinical response seen and supports the further development of our Bria-IMT regimen. Women with metastatic breast cancer continue to have poor survival despite recently approved therapies and further development of novel treatments remains an area of high unmet medical need," stated Dr. Giuseppe Del Priore, Briacell's chief medical officer.

The Bria-IMT combination regimen is currently undergoing a pivotal phase 3 study in advanced breast cancer.

About Briacell Therapeutics Corp.

Briacell is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care.

We seek Safe Harbor.